CVC Capital Partners thought it could quietly take Recordati private with a 10.7 billion euro bid. Instead, the private equity giant walked into a shareholder revolt that exposes the growing divide between buyout firms and the public-market investors they're trying to squeeze out.

CVC and Belgium's Groupe Bruxelles Lambert launched their voluntary takeover offer in May at 51.29 euros per share, aiming to delist the Milan-based pharmaceutical company and tighten control over its rare disease portfolio. CVC already holds 46.82 percent of Recordati through its Rossini vehicle, so on paper, the deal looked like a formality. Three months later, six minority shareholders are pushing back, and activist investor Palliser Capital is accusing CVC of trying to "railroad" investors into accepting a "lowball price."

The Accusation That Could Derail the Deal

Palliser Capital's letter to Recordati's board didn't mince words. The London-based activist accused CVC of pressuring minority shareholders into selling at a price that undervalues Recordati's rare disease assets and growth trajectory. Several long-only investors echoed the complaint, raising concerns about the governance of the proposed deal and whether CVC used its majority stake to dictate terms that favor the buyout firm over public shareholders.

The 51.29 euro offer represents a premium to where Recordati traded before the bid was announced, but these investors argue the premium doesn't reflect the company's strategic value. Recordati operates in rare diseases, a pharmaceutical niche with limited competition and pricing power that typically commands higher valuations. CVC's offer, they claim, captures the company's current earnings but ignores the long-term value of its orphan drug portfolio.

Why This Revolt Matters Beyond One Deal

This isn't just about Recordati. It's about whether private equity firms can use majority stakes to force out minority shareholders at prices that benefit the buyout firm more than the investors being bought out. CVC's 46.82 percent holding gives it effective control, but it still needs minority shareholders to tender their shares for the delisting to work smoothly. Those shareholders now have leverage, and they're using it to demand a higher price or block the deal entirely.

The revolt also reveals a structural tension in European markets. Buyout firms have spent the past decade accumulating large stakes in public companies, then attempting to take those companies private at valuations that reflect their power as majority shareholders rather than the fair market value of the business. When minority shareholders push back, as they're doing with Recordati, the private equity playbook breaks down.

Recordati's Rare Disease Portfolio Under Scrutiny

Recordati's assets include treatments for rare disorders that face minimal competition and generate stable cash flows. These are exactly the kind of businesses that private equity targets because they're predictable, defensible, and can support leverage. But they're also valuable to public-market investors for the same reasons, and those investors argue that CVC's offer doesn't compensate them for giving up long-term exposure to that cash generation.

The company has operated for a century, and its presence on the Milan stock exchange provided liquidity and transparency for Italian investors. CVC's take-private would remove that liquidity and put Recordati's fate entirely in the hands of a buyout firm that answers to its own limited partners, not public shareholders. That's a trade-off some investors are willing to make at the right price. At 51.29 euros per share, they're saying the price isn't right.

The Governance Questions That Won't Go Away

Palliser Capital and the other objecting shareholders are pointing to governance concerns that go beyond price. They want to know whether Recordati's board fulfilled its fiduciary duty to minority shareholders or whether it deferred to CVC's interests as the majority owner. They're questioning whether the deal process included a genuine market check or whether CVC's control meant no other bidders had a realistic chance of competing.

These are the questions that slow down take-private transactions and force buyout firms to either raise their bids or walk away. CVC has the capital to increase its offer if the revolt spreads, but doing so would set a precedent that minority shareholders can extract higher prices by organizing opposition. Every other private equity firm attempting a similar deal would face the same pressure.

What Comes Next for CVC and Recordati

CVC has three choices. It can stick with the 51.29 euro offer and hope enough minority shareholders tender to reach the threshold for delisting. It can raise the bid to appease opponents and ensure the deal closes smoothly. Or it can maintain its majority stake but abandon the take-private, leaving Recordati listed and continuing to generate returns for both CVC and the minority investors who refused to sell.

The outcome will signal whether shareholder revolts can actually stop private equity deals in Europe or whether CVC's existing control makes resistance futile. Either way, the Recordati fight has already accomplished something: it's shown that minority shareholders are no longer willing to accept lowball prices just because the majority owner demands it. That's a problem for every buyout firm trying to take a public company private on terms that favor the buyer over the shareholders being bought out.